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OBJECTIVES: To give a systematic overview on pub-
lished decision-analytic studies and methodological
approaches in the evaluation of therapies in Parkinson’s
disease (PD) and derive generic recommendations for
future PD decision models. METHODS: A systematic lit-
erature review was performed to identify studies that
evaluated interventions for PD using mathematical
models. Using a standardized assessment form, informa-
tion on methodological framework, results, limitations
and conclusions were extracted from publications and
reported in systematic evidence tables. The evidence on
strengths and limitations was summarized in recommen-
dations for further PD modeling. RESULTS: We identi-
ﬁed 8 studies [1–8] that used mathematical models to
evaluate the effect of different pharmaceutical and surgi-
cal treatment options in PD in different settings and coun-
tries. Modeling approaches comprised mathematical
equations as well as decision-trees and Markov models
with a time horizon ranging from 5 years to lifetime. All
models based progression on the evolution of clinical sur-
rogate endpoints and included economic consequences.
No model is currently available that encompasses both
the underlying biologic disease progression and the spec-
trum of all relevant complications, and in addition, links
them to patient preferences as well as to economic out-
comes. CONCLUSIONS: A generic and ﬂexible decision
model for PD, that can be applied to different treatment
strategies should consider the entire spectrum of clinically
relevant outcomes and complications during an ade-
quately long time horizon and should be externally vali-
dated. Models for economic evaluations adoping a
societal perspective should include patient preferences
and all relevant economic consequences including those
of adverse events. Evaluating early diagnosis in combina-
tion with neuroprotective therapies requires the use of
health states that represent the natural history of the
disease in untreated patients such as Hoehn & Yahr off
stages or histologically deﬁned health states.
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ENSURING A STANDARD USER INTERFACE FOR
MODELS: MODEL-IT
Caro JJ, Magno LL
Caro Research Institute, Concord, MA, USA
Cost-containment pressures worldwide are increasing the
demand on drug developers to demonstrate the value of
products in order to obtain reimbursement. To meet this
demand, developers are turning to economic models.
While models are informative tools, they can be expen-
sive to produce, their complexity makes them difﬁcult to
understand and the lack of standardized formatting
makes them hard to navigate. OBJECTIVE: To develop
a low cost tool that allows model results to be viewed in
a standard format and to increase interdisciplinary access
models in order to support wider use in the development
and marketing of new pharmaceuticals. METHODS: An
electronic viewer (MODEL-IT) was developed as a “con-
tainer” to display and run analyses of disease models.
Building on the widespread familiarity of Windows©, the
tool was programmed to work as a stand-alone applica-
tion in a Win2000, WinXT, or WinNT environment.
Screens were developed to display inputs and outcomes
pertinent to the model being analyzed, while maintaining
a consistent format. Incorporation of point and click tech-
nology was used to simplify model functions by pro-
gramming buttons to carry out speciﬁc tasks. RESULTS:
The MODEL-IT tool breaks input parameters into spe-
ciﬁc categories including drug efﬁcacy, population 
characteristics and country-speciﬁc costs. All ﬁelds are
editable. Outcomes are model-speciﬁc and include costs,
survival and cost-effectiveness. Model edits can be saved
for later use, printed and exported to other programs. To
allow users access to detailed model information, the
technical manual can be accessed through a button
control. CONCLUSIONS: Current trends in the in-
creased use of pharmacoeconomic analysis will demand
standardization of models to streamline efﬁciency and
transfer expertise to multidisciplinary users. Standardized
user interfaces will become increasingly important in
meeting these needs.
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THE USE OF A SEMI-MARKOV PROCESS MODEL
IN COST-EFFECTIVENESS MODELING: THE
CASE OF ANTI-EPILEPTIC DRUGS
Hawkins NS, Epstein D, Sculpher M
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OBJECTIVE: Markov models are often used as part of
cost-effectiveness analysis to extrapolate from short-term
experimental evidence. Most Markov models used in 
economic evaluation typically assume ﬁxed transition
probabilities with respect to time. This is because imple-
mentation of time-dependant probabilities for all states is
difﬁcult in widely used modeling software. This is a lim-
iting assumption when transitions are clearly time depen-
dent. In such circumstances, semi-Markov processes, with
time-dependent probabilities, may be necessary to
provide reliable estimates of cost-effectiveness. ME-
THODS: The implementation of a semi-Markov process
will be illustrated using a recent analysis of anti-epileptic
drug sequences for the National Institute for Clinical
Excellence. In this case study, the probability of treatment
failure was dependant on the time spent on the current
treatment. Although such models can be implemented in
Excel or other modeling applications, the large number
of states required makes this cumbersome. As an alter-
native, the model was realized using “R”, a statistical 
